Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes. Methods: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germ...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2023-03-01
Rangatū:	International Journal of Infectious Diseases
Ngā marau:	Heterologous prime-boost ChAdOx1-S BNT162b2 Immunogenicity Reactogenicity
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S1201971222006725
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!